Behcet syndrome (BS) is a chronic systemic inflammatory disorder involving vessels of all sizes, characterized by episodes relative of oral and / or genital ulcers, as well as cutaneous lesions. The participation of the occult, vascular, gastrointestinal neurological system can cause significant morbidity and mortality. Glucocorticoids and immunosuppressants are the cornerstones of the management of the BS. Biological agents have been recommended for serious and / or refractory BS. Interferon-α (IFN-α) had several biological effects, such as antiviral and antiproliferative, which can regulate innate and adaptive immunity in BS. The growing evidence has shown the effectiveness of IFN-α in severe and / or refractory BS. Numerous studies have shown that IFN-α has comparable efficiency and tolerance profiles as anti-tumorized necrosis (TNF) factor agents for BehCet uveitis with much lower cost effects. and steroid and immunosuppressor.
IFN-α has been recommended as second-line processing for Ocular participation of BS in Eula (the European League Against Rheumatism) 2018. IFN-α also improves mucocutaneous lesions at BS with the dose of 3 to 9-12 Millions of IU three times a week. Some cases indicated the therapeutic potential of IFN-α in intestinal Bs. As a new IFN-α test in vascular BS (VBS), a recent study revealed the lower relapse rate and the higher reconditionalization rate with the thrombosis of the deep vein of the lower limbs (DVT). Two other case reports presented the effectiveness of IFN-α in the participation of the pulmonary artery in BS. In addition, case reports have shown successful treatment in refractory neurological participation.
There are two subtypes of IFN-α commonly used in autoimmune diseases, named IFN-α2a and IFN-α2B. IFN-α2A seemed more effective than IFN-α2B, particularly in the ocular and mucous participation of BS. The side effects of IFN-α are dependent on dose and non-serious. The most common side effects are flu syndrome, soft leukopenia and alopecia. Given the potential risk of tuberculosis (TB) and hepatitis B (HBV) reactivation of TNF-α inhibitors, IFN-α is safe because of its anti-VHB effect and effect. protection on tuberculosis. In conclusion, IFN-α is a promising choice for severe and / or refractory BS patients, particularly for those who are intolerant or opposable to other biological agents, such as TNF inhibitors. Other prospective controlled studies are justified to confirm the effectiveness and safety of IFN-α in BS.
Type I Interferon (IFN) – Geographic activation of canonical and non-canonic signaling pathways
For several decades, the accumulation of evidence has involved involving type I interferons (IFNS) as key elements of the immune response. Therapeutic approaches incorporating different recombinant type IFN type proteins have been used successfully to treat a diverse group of diseases with significant and positive results. The biological activities of Type I IFNs are consequences of signaling events occurring in the cytoplasm and cell core.
The biochemical events involving JAK / STAT proteins that control the activation of the transcription of the genes stimulated by the IFN (ISG) were the first to be identified and are called “canonical” signaling. The subsequent identification of JAK / statistics independent signaling routes, critical for translating ISG and / or mRNA transcription, are noted “non-canonical” or “non-classical” channels. In this review, we summarize these signaling cascades and discuss recent developments in the field, particularly with regard to the biological and clinical implications of the engagement of canonical and non-canonical channels.
[Progress in interferon: A treatment of Behcet syndrome]
Justification for Covid-19 treatment with nebulized interferon-β-1B-review of the literature and a personal preliminary experience
The inflammatory response to Covid-19 is specifically associated with a type I interferon response type I (IFN) and a complete comprehensive blockade of IFN-β secretion. Clinically, the nebulization of IFN-α-2B has been historically used in China to treat viral pneumonia associated with SARS-VOCs. Very recent data show that the use of an inhaled type I IFN is associated with a decrease in mortality in Chinese patients Covid-19. However, the nebulization of IFN is currently not standard in Europe and the United States. As a result, our group has put in place a project to assess the possibility of nebulizing IFN-β-1b (a drug currently used in Europe to treat multiple multiple sclerosis via subcutaneous injections) and to evaluate
The safety of this new mode of administration in COV-2 infected patients. We present here data from the literature that have allowed us to build our hypothesis and develop collaboration between clinical pharmacists, intensivists and nebulization engineers in order to obtain a first pre-clinical and clinical experience of IFN- nebulization. β-1b. After the validation of the nebulization method and the verification of the drop size compatible with the nebulization, the method has been applied to four intensive care patients treated at our university hospital, for which none of the civid-19 therapies initially used in France has led to an important clinical improvement. All patients showed a negative viral car and experienced clinical improvement 7-16 days after initiating the nebulized inhalation therapy of IFN-β-1B. No side effects have been observed. All patients were alive in a 90-day follow-up.
Description: Many solid tumors contain heterogeneous populations of normal and cancerous cells. Separation of these cell populations is key to an accurate assessment of the true genotypic and phenotypic differences between normal and tumor cells. Our CytoSelect Clonogenic Tumor Cell Isolation Kit uses a proprietary semisolid agar medium to facilitate formation of colonies by cells from solid tumors. Colonies are grown in either a 6-well plate or a 35mm culture dish. These colonies are isolated away from single (i.e. normal) cells by size filtration. The viable cells from these colonies can be easily recovered for further analysis.
Description: Many solid tumors contain heterogeneous populations of normal and cancerous cells. Separation of these cell populations is key to an accurate assessment of the true genotypic and phenotypic differences between normal and tumor cells. Our CytoSelect Clonogenic Tumor Cell Isolation Kit uses a proprietary semisolid agar medium to facilitate formation of colonies by cells from solid tumors. Colonies are grown in either a 6-well plate or a 35mm culture dish. These colonies are isolated away from single (i.e. normal) cells by size filtration. The viable cells from these colonies can be easily recovered for further analysis.
cDNA - Human Tumor Tissue: Lymphoma, Hodgkin's Disease
Description: Leukocyte or tumor cell interactions with vascular endothelium consist of a cascade of processes including the firm attachment of cells to endothelial cell adhesion molecules. The CytoSelect Tumor Endothelium Adhesion Assay provides a robust system for the quantitative determination of interactions between tumor cells and endothelium. Adherent cells can be easily quantified on a fluorescence plate reader.
Description: Cancer cell transmigration, particularly extravasation, is an important step in cancer metastasis. It is the final step in a cascade of interactions between cells and the endothelium. CytoSelect Tumor Transendothelial Migration Assay provides a robust system for the quantitative determination of transmigrations and interactions between endothelium and tumor cells. Migratory cells may be quantified on a fluorescence plate reader. Kits use 24-well plates with 8 µm pore size membrane inserts.
Description: The 293AD Cell Line is derived from the parental 293 cells but selected for attributes that increase adenovirus production, including firmer attachment and larger surface area.
Description: The 293AAV Cell Line is derived from the parental 293 cells but selected for attributes that increase AAV production, including firmer attachment and larger surface area.
Description: The 293LTV Cell Line is derived from the parental 293 cells but selected for attributes that increase lentiviral production, including fimrer attachment and larger surface area.
Description: The 293RTV Cell Line is derived from the parental 293 cells but selected for attributes that increase retroviral production, including fimrer attachment and larger surface area.
Description: This cell lysate is prepared from human mcf-7 using Boster's RIPA Lysis Buffer (AR0105) using a standard whole cell lysate protocol. The concentration was determined using the BCA assay process and then diluted using Dithiothreitol (DTT) and a reducing SDS sample loading buffer, heated for 5 minutes at 100˚C.
Description: Traditionally, the soft agar colony formation assay has been used to monitor anchorage-independent growth. Cells proliferate for 3-4 weeks in a semisolid culture medium, followed by tedious manual counting of colonies. Our CytoSelect 96-Well In Vitro Tumor Sensitivity Assay provides a stringent, anchorage-independent model for chemosenstivity testing and screening of potential anticancer drugs. After just 6-8 days, cell colonies are quantified using a standard colorimetric microplate reader.
CytoSelect 96-well In Vitro Tumor Sensitivity Assay (Soft Agar Colony Formation)
Description: Traditionally, the soft agar colony formation assay has been used to monitor anchorage-independent growth. Cells proliferate for 3-4 weeks in a semisolid culture medium, followed by tedious manual counting of colonies. Our CytoSelect 96-Well In Vitro Tumor Sensitivity Assay provides a stringent, anchorage-independent model for chemosenstivity testing and screening of potential anticancer drugs. After just 6-8 days, cell colonies are quantified using a standard colorimetric microplate reader.
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-E cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection.
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-GP cells contain the gag and pol genes required for retroviral packaging; an expression vector is co-transfected with a VSVG envelope vector.
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-A cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection.
Total Protein - Murine Embryonic Stem Cell Line D3
Description: Traditionally, the soft agar colony formation assay has been used to monitor anchorage-independent growth. Cells proliferate for 3-4 weeks in a semisolid culture medium, followed by tedious manual counting of colonies. Our CytoSelect 96-Well In Vitro Tumor Sensitivity Assay provides a stringent, anchorage-independent model for chemosenstivity testing and screening of potential anticancer drugs. After just 6-8 days, cell colonies are quantified using a standard colorimetric microplate reader.
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis.
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis.
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis.
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis.
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis.
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis.
Paraffin Tissue Section - Human Bone Tumor: Giant Cell Tumor, Grade I-II
Description: MCF 7 (Human breast Adenocarcinima) cell membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The MCF 7 (Human breast Adenocarcinima) cell was frozen in liquid nitrogen immediately after excision and then stored at -70ºC. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated MCF 7 (Human breast Adenocarcinima) cell membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated MCF 7 (Human breast Adenocarcinima) cell membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis.
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis.
Multiple organs tumor with normal tissue array and cell line samples
Description: Cell Biolabs? Collagen-based Contraction Assay Kit provides a simple system to assess cell contractivity in vitro and screen cell contraction mediators. Each kit provides sufficient quantities to perform up to 24 assays in a 24-well plate. The kit can be also used in culturing cells in 3D collagen matrix.
Description: Cell Biolabs? CytoSelect MTT Cell Proliferation Assay provides a colorimetric format for measuring and monitoring cell proliferation. The kit contains sufficient reagents for the evaluation of 960 assays in 96-well plates or 192 assays in 24-well plates. Cells can be plated and then treated with compounds or agents that affect proliferation. Cells are then detected with the proliferation reagent, which is converted in live cells from the yellow tetrazole MTT to the purple formazan form by a cellular reductase (Figure 1). An increase in cell proliferation is accompanied by an increased signal, while a decrease in cell proliferation (and signal) can indicate the toxic effects of compounds or suboptimal culture conditions. The assay principles are basic and can be applied to most eukaryotic cell lines, including adherent and non-adherent cells and certain tissues. This cell proliferation reagent can be used to detect proliferation in bacteria, yeast, fungi, protozoa as well as cultured mammalian and piscine cells.
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap.
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap.
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap.
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap.
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap.
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap.
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap.
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap.
Description: Cell Biolabs? HIF-1 Cell Based ELISA Kit is an immunoassay developed for rapid detection of HIF-1 Alpha in fixed cells. Cells on a microplate are stimulated for HIF-1 Alpha stabilization, fixed, permeabilized, and then neutralized in the well. HIF-1 Alpha is then detected with an anti-HIF-1 alpha antibody followed by an HRP conjugated secondary antibody. Each kit provides sufficient reagents to perform up to a total of 96 assays and can detect HIF-1 Alpha from human, mouse, or rat.
Description: The CytoSelect BrdU Cell Proliferation ELISA Kit detects BrdU incorporated into cellular DNA during cell proliferation using an anti-BrdU antibody. When cells are incubated in media containing BrdU, the pyrimidine analog is incorporated in place of thymidine into the newly synthesized DNA of proliferating cells. Once the labeling media is removed, the cells are fixed and the DNA is denatured in one step with a fix/denature solution (denaturation of the DNA is necessary to improve the accessibility of the incorporated BrdU for detection). Then an anti-BrdU mouse monoclonal antibody is added followed by an HRP conjugated secondary antibody to detect the incorporated BrdU. The magnitude of the absorbance for the developed color is proportional to the quantity of BrdU incorporated into cells and can be directly correlated to cell proliferation.
Description: Our CytoSelect 96-Well Cell Transformation Assay (Soft Agar Colony Formation) is suitable for measuring cell transformation where no downstream analysis is required. Cells are incubated in a semisolid agar medium for 7-8 days. The cells are then solubilized, lysed and detected using the included fluorescent dye in a fluorometric plate reader.
Description: Our CytoSelect 96-Well Cell Transformation Assay (Soft Agar Colony Formation) is suitable for measuring cell transformation where no downstream analysis is required. Cells are incubated in a semisolid agar medium for 7-8 days. The cells are then solubilized, lysed and detected using the included fluorescent dye in a fluorometric plate reader.
Description: The ability of malignant tumor cells to invade normal surrounding tissue contributes in large part to the morbidity and mortality of cancers. Cell invasion requires several distinct cellular functions including adhesion, motility, detachment, and extracellular matrix proteolysis. Our CytoSelect Cell Invasion Assays utilize precoated inserts to assay the invasive properties of tumor cells. Invasive cells can be quantified in 24-well plates on either a standard microplate reader or a fluorescence plate reader. Inserts are precoated on the top of the membrane with ECM matrix gel (basement membrane), a protein mix isolated from EHS tumor cells.
Description: The ability of malignant tumor cells to invade normal surrounding tissue contributes in large part to the morbidity and mortality of cancers. Cell invasion requires several distinct cellular functions including adhesion, motility, detachment, and extracellular matrix proteolysis. Our CytoSelect 96-Well Cell Invasion Assays utilize precoated inserts to assay the invasive properties of tumor cells. Invasive cells can be quantified in 96-well plates on a fluorescence plate reader. Inserts are precoated on the top of the membrane with Basement Membrane, an ECM protein mix isolated from EHS tumor cells.
Description: The CytoSelect Cell Viability and Cytotoxicity Assay Kit provides a simple format for monitoring cell viability via metabolic activity. Live cells are detected with either MTT (colorimetric detection) or Calcein AM (fluorometric detection). Dead cells are detected by EthD-1 reagent (fluorometric). All 3 detection reagents are included, along with Saponin (a cell death initiator). Prior to the assay, cells may be treated with compounds or agents that affect cell viability. This kit is suitable for eukaryotic cells, not yeast or bacteria.
Description: CytoSelect 24-Well Cell Co-Culture System provides a unique platform to monitor direct contact between two cell types in a single well. First, cells are cultured until they form a monolayer around the insert, creating a defined 8 mm cell-free zone. Once the insert is removed, a second cell type may be seeded into the exposed zone. The kit contains proprietary treated inserts and sufficient reagents for the evaluation of 24 samples. The inserts are compatible with most adherent cell types and experimental conditions.
Description: CytoSelect 24-Well Cell Co-Culture System provides a unique platform to monitor direct contact between two cell types in a single well. First, cells are cultured until they form a monolayer around the insert, creating a defined 8 mm cell-free zone. Once the insert is removed, a second cell type may be seeded into the exposed zone. The kit contains proprietary treated inserts and sufficient reagents for the evaluation of 24 samples. The inserts are compatible with most adherent cell types and experimental conditions.
Description: Cell Biolabs? Cell Contraction Assays (Floating Matrix Model) provide a simple, in vitro system to assess cell contractivity and screen cell contraction mediators. The proprietary Cell Contraction Plate eliminates the matrix releasing step of the conventional contraction assay, providing a faster, higher-throughput method to assess cell contraction.
Description: Cell Biolabs? CytoSelect Cell Proliferation Assay Reagent (Fluorometric) provides a fluorometric format for measuring and monitoring cell proliferation. Cells can be plated and then treated with compounds or agents that affect proliferation. Cells are then incubated with the proliferation reagent. Upon entering metabolically active live cells, the non-fluorescent proliferation reagent is converted into a bright red fluorescent form. An increase in cell proliferation is accompanied by increased fluorescent signal, while a decrease in cell proliferation (and signal) can indicate the toxic effects of compounds or suboptimal culture conditions. The assay principles are basic and can be applied to most eukaryotic cell lines, including adherent and non-adherent cells and certain tissues. This cell proliferation reagent can be used to detect proliferation in bacteria, yeast, fungi, protozoa as well as cultured mammalian and piscine cells. The kit contains sufficient reagents for the evaluation of 960 assays in ten 96-well plates or 192 assays in eight 24-well plates.
Description: Cell Biolabs? CytoSelect WST-1 Cell Proliferation Assay Reagent provides a colorimetric format for measuring and monitoring cell proliferation. The 10 mL volume is sufficient for the evaluation of 960 assays in ten 96-well plates or 192 assays in eight 24-well plates. Cells can be plated and then treated with compounds or agents that affect proliferation. Cells are then detected with the proliferation reagent, which is converted in live cells from WST-1 to the formazan form in the presence of cellular NADH and an electron mediator. An increase in cell proliferation is accompanied by increased signal, while a decrease in cell proliferation (and signal) can indicate the toxic effects of compounds or suboptimal culture conditions. The assay principles are basic and can be applied to most eukaryotic cell lines, including adherent and non-adherent cells and certain tissues. This cell proliferation reagent can be used to detect proliferation in bacteria, yeast, fungi, protozoa as well as cultured mammalian and piscine cells.
×
Although it is not possible to draw firm conclusions on the effectiveness of the processing based on this case report, our study shows that IFN-β-1b pulmonary administration is feasible, with a good safety profile. This procedure, which has the advantage of directly targeting lungs and reducing the risks of systemic side effects, can represent a promising therapeutic strategy for supporting patients with severe Covid-19. However, our preliminary observation requires confirmation through randomized controlled trials.
Ricardo![[Progress in interferon: A treatment of Behcet syndrome]](https://ifn-a.com/wp-content/uploads/2020/12/IMG-20201217-WA0104.jpg)
![[Progress in interferon: A treatment of Behcet syndrome]](https://ifn-a.com/wp-content/uploads/2020/12/IMG-20201217-WA0104-142x300.jpg)